INSIGHT FROM ROCHE
LINK TO CGMS
Insulet Omnipod's upcoming
Horizon is due to work with
both Abbott and Dexcom CGMs.
As announced earlier this year,
Insulet unveiled partnerships these
companies which both have an
on-body sensor for blood glucose
tracking. Insulet announced plans
to integrate Abbott's FreeStyle
Libre 2 (still under FDA review)
and Dexcom's G6, and upcoming
G7 CGMs (due to launch in 2021),
into Insulet's Omnipod Horizon
automated insulin delivery (AID)
system (due to launch in 2021).
AID systems use CGM and smart
algorithms to automatically adjust
insulin delivery via an insulin pump
or pod. These 'dual partnerships'
mean that Horizon will be the first
AID system with two CGM partners
with the aim of keeping users within
their target blood sugar range.
Insulet's tubeless insulin delivery
pod is a three-day-wear patch
pump, which will communicate
with a CGM to deliver insulin. Users
control the system directly from
their smartphone. A pivotal trial of
the system is underway.
As reported by DiaTribe.
The French company Diabeloop
announced on 1 March 2021 that
it has integrated the Accu-Chek
Insight insulin pump from Roche into
its DBLG1 System. The automated
and personalized solution for Type
1 diabetes management will be
available in select European countries
in early 2021.
DBLG1 System, the AID
(Automated Insulin Delivery) system
from Diabeloop individualizes
treatment by automating insulin
decisions. It connects a CGM
(Continuous Glucose Monitoring),
an insulin pump and Diabeloop's
self-learning algorithm hosted in a
dedicated handset to function as a
hybrid-closed loop. The algorithm
analyses data in real time and takes
into account the physiology, history
and data entries (meals or exercise)
to determine either to maintain
current settings, adjust or even
stop basal insulin delivery to avoid a
predicted low/high or deliver a bolus
to correct a high.
With the integration of the AccuChek Insight
insulin pump, Diabeloop
and Roche offer people with
diabetes the possibility to choose
an automated and personalized
management using a sleek-designed
and pre-filled insulin cartridge pump.
Erik Huneker, founder and
CEO of Diabeloop commented,
"Diabeloop's long standing mission
is to relieve people with diabetes
of their constant day and night
burden and offer them more
personalized solutions. Combining
our self-learning algorithm with the
reliability and accuracy of the AccuChek Insight
insulin pump allows
Diabeloop and Roche to propose a
safe, easy-to-use and individualized
treatment management solution, so
that people with diabetes can live
their life without interruption."
Meanwhile Marcel Gmuender,
Head of Roche Diabetes Care, added,
"Automated insulin delivery is a big
step towards true relief for people
with diabetes. The Accu-Chek Insight
insulin pump will be the first pump
with a pre-filled cartridge that can be
operated in hybrid-closed loop mode.
Together with Diabeloop, we strive
to bring a unique, holistic approach
of automated insulin delivery
to people with Type 1 diabetes
supporting their self-management
of constantly adjusting their insulin
dose and thus enabling them to
manage their condition more easily
in everyday life."
A European roll-out is expected to
begin sometime in 2021.
To read more about Diabeloop,
see our feature on p.34 of our
February issue HERE.
Caption to go here for the two images.
TIME IN RANGE
A study has found that time in range
(TIR) is associated with, and likely
enhances, daily mood in adults with
T1D. Researchers W H Polonsky and A
L Fortmann followed a cohort of 219
adults with Type 1 using real-time CGM
systems. The daily changes in CGM
metrics were associated with nightly
reports of positive and negative mood
over two weeks. Greater daily TIR and
less time in 'severe' hyperglycaemia
were significantly associated with
higher ratings on all positive mood
elements and lower ratings on most
negative mood elements.